Expression and Clinical Significance of OX40 and OX40L MRNA in Hepatocellular Carcinoma

Overview

Journal Bull Exp Biol Med

Publisher Springer

Specialty General Medicine

Date 2021 Mar 13

PMID 33713232

Citations 3

Authors

P Du

Z Wang

J Geng

Y Wang

Affiliations

Soon will be listed here.

Abstract

In a retrospective study, the expression of mRNA of membrane receptor OX40 and its ligand OX40L in liver tissues was analyzed in 34 patients with hepatocellular carcinoma in order to assess their clinical implications and prognostic value. Expression of mRNA was analyzed by reverse transcription PCR and TaqMan probes. Expression of OX40 mRNA was significantly higher in tumor specimens in paired comparison with the samples of adjacent non-tumor tissue or normal liver tissue of control patients. In contrast, expression of OX40L mRNA was lower in tumor tissue in paired comparison with the samples of adjacent non-tumor tissue or normal liver tissue. The clinical and pathological analysis showed that expression of OX40 mRNA significantly correlated with the degree of tumor differentiation; there was an insignificant decreasing trend in the length of recurrence-free period. It was hypothesized that microenvironment of hepatocellular carcinoma can induce immunosuppression due to dysregulation of the expression of OX40 and OX40L in tumor tissue, which promotes tumor growth.

Citing Articles

Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.

Rakke Y, Buschow S, IJzermans J, Sprengers D Front Immunol. 2024; 15:1357333.

PMID: 38440738 PMC: 10910082. DOI: 10.3389/fimmu.2024.1357333.

Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer.

Wang L, Zeng Q, Jiang S, Chen Z, Wang X, Li L Front Oncol. 2022; 12:987481.

PMID: 36425563 PMC: 9679423. DOI: 10.3389/fonc.2022.987481.

A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma.

Xie Y, Zhang W, Sun J, Sun L, Meng F, Yu H Sci Rep. 2022; 12(1):18514.

PMID: 36323801 PMC: 9630496. DOI: 10.1038/s41598-022-22962-y.

References

Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria J, Zitvogel L, Marabelle A . Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer. 2015; 52:50-66. DOI: 10.1016/j.ejca.2015.08.021. View

Attanasio J, Wherry E . Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity. 2016; 44(5):1052-68. PMC: 4873956. DOI: 10.1016/j.immuni.2016.04.022. View

Buchan S, Rogel A, Al-Shamkhani A . The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2017; 131(1):39-48. DOI: 10.1182/blood-2017-07-741025. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Deng J, Zhao S, Zhang X, Jia K, Wang H, Zhou C . OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer. Onco Targets Ther. 2019; 12:7347-7353. PMC: 6735535. DOI: 10.2147/OTT.S214211. View

He Y, Zhang X, Jia K, Dziadziuszko R, Zhao S, Deng J . OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Transl Lung Cancer Res. 2019; 8(4):352-366. PMC: 6749115. DOI: 10.21037/tlcr.2019.08.15. View

Metzger T, Long H, Potluri S, Pertel T, Bailey-Bucktrout S, Lin J . ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. Cancer Res. 2016; 76(13):3684-9. DOI: 10.1158/0008-5472.CAN-15-3412. View

Virani N, Thavathiru E, McKernan P, Moore K, Benbrook D, Harrison R . Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018; 425:174-182. DOI: 10.1016/j.canlet.2018.03.027. View

Wang Z, Zhang N, Song R, Fan R, Yang L, Wu L . Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation. Oncol Lett. 2015; 10(1):143-148. PMC: 4487098. DOI: 10.3892/ol.2015.3248. View

10.

Webb G, Hirschfield G, Lane P . OX40, OX40L and Autoimmunity: a Comprehensive Review. Clin Rev Allergy Immunol. 2015; 50(3):312-32. DOI: 10.1007/s12016-015-8498-3. View

11.

Weinberg A, Morris N, Kovacsovics-Bankowski M, Urba W, Curti B . Science gone translational: the OX40 agonist story. Immunol Rev. 2011; 244(1):218-31. PMC: 3622727. DOI: 10.1111/j.1600-065X.2011.01069.x. View

12.

Wu C, Tsai Y, Lee I, Wu P, Lu L, Tsao W . Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment. Oncoimmunology. 2018; 7(9):e1477459. PMC: 6140549. DOI: 10.1080/2162402X.2018.1477459. View

13.

Zhong B, Ping Huang M, Yin G, Gao X . Effects of costimulation on intrahepatic immunopathogenesis in patients with chronic HBV infection. Inflamm Res. 2013; 63(3):217-29. PMC: 3921453. DOI: 10.1007/s00011-013-0691-3. View